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Abstract 
The control of smallpox was achieved using live vaccinia virus (VV) vaccine, which 
successfully eradicated the disease worldwide. As the variola virus no longer exists as a 
natural infection agent, mass vaccination was discontinued after 1980. However, emergence 
of smallpox outbreaks caused by accidental or deliberate release of variola virus has 
stimulated new research for second-generation vaccine development based on attenuated VV 
strains. Considering the closely related animal poxviruses that also arise as zoonoses, and the 
increasing number of unvaccinated or immunocompromised people, a safer and more 
effective vaccine is still required. With this aim, new vectors based on avian poxviruses that 
cannot replicate in mammals should improve the safety of conventional vaccines, and protect 
from zoonotic orthopoxvirus diseases, such as cowpox and monkeypox. In this study, DNA 
and fowlpox (FP) recombinants that expressed the VV L1R, A27L, A33R, and B5R genes 
were generated (4DNAmix, 4FPmix, respectively) and tested in mice using novel 
administration routes. Mice were primed with 4DNAmix by electroporation, and boosted with 
4FPmix applied intranasally. The lethal VVIHD-J strain was then administered by intranasal 
challenge. All of the mice receiving 4DNAmix followed by 4FPmix, and 20% of the mice 
immunized only with 4FPmix, were protected. The induction of specific humoral and cellular 
immune responses directly correlated with this protection. In particular, higher anti-A27 
antibodies and IFN-producing T lymphocytes were measured in the blood and spleen of the 
protected mice, as compared to controls. VVIHD-J neutralizing antibodies in sera from the 
protected mice suggest that the prime/ boost vaccination regimen with 4DNAmix plus 
4FPmix may be an effective and safe mode to induce protection against smallpox and 
poxvirus zoonotic infections. The electroporation/ intranasal administration routes contributed 
to effective immune responses and mouse survival.  
 
 4    
Keywords: Recombinant vaccines; Fowlpox virus; prime/ boost; OPXV vaccine; L1R, A27L, 
A33R, B5R VV genes; intranasal mucosal vaccination  
 5    
1. Introduction 
New infectious diseases are continuously emerging, and the lack of efficient immune 
prevention requires development of novel vaccines and vaccination strategies. Due to 
successful eradication of smallpox worldwide, the use of the vaccinia virus (VV) vaccine that 
was administered by scarification was discontinued or was replaced by VV-derived cultured 
immunogens (Weltzin et al., 2003). However, serious side effects can result from the 
traditional vaccine (Ferrier-Rembert et al., 2008), especially in immunocompromised people 
(Jacobson et al., 2008; Lane & Goldstein, 2003) and in patients with skin diseases (Schulze et 
al., 2007). Thus, a new generation of attenuated vaccines has been developed to decrease 
undesired effects, and to face the potential re-emergence in the human population through 
accidental or deliberate release of orthopoxviruses (OPXVs) (Megid et al., 2012; Vogel et al., 
2012; Whitley, 2003). In this regard, although not as lethal as the variola virus, the monkeypox 
virus (MPXV) also represents a threat to public health, as it causes mortality in 
underdeveloped countries (Reed et al., 2004) and can become a potential bioweapon if adapted 
to grow and spread in humans (Lewis-Jones, 2004).  
Previous studies have demonstrated that, after the conventional vaccination, 
neutralizing antibodies were mainly raised against surface proteins of both the VV 
extracellular virions (e.g., A33, B5) and the intracellular mature virions released after cell 
lysis (e.g., L1, A27) (Moss, 2011; Roberts & Smith, 2008; Smith et al., 2002). Therefore, 
subunit vaccines have been designed based on plasmids that express the VV L1R, A27L, 
A33R, and B5R genes. These have been shown to be protective in mice after intranasal (i.n.) 
VVIHD-J challenge, and in monkeys after intravenous MPXV inoculation (Buchman et al., 
2010; Fogg et al., 2007; Hirao et al., 2011).  
Attenuated avipoxviruses, and in particular canarypox and fowlpox (FP) viruses, have 
also been developed as novel vectors for the construction of recombinant vaccines against 
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several human infectious diseases (Radaelli et al., 1994; Zanotto et al., 2010). These vectors are 
naturally restricted to avian species for their replication, although they are permissive for entry 
and transgene expression in most mammalian cells. In these cells, they undergo abortive 
replication and express early and late viral products, but no mature infectious viruses 
(Somogyi et al., 1993). Moreover, because of the absence of cross-reactivity with VV, 
avipoxviruses can also escape neutralization by vector-generated antibodies in smallpox-
vaccine-experienced humans (Baxby & Paoletti, 1992). 
Previous studies have also shown that systemic delivery of FP-based vaccines in 
humans is safe and does not cause adverse effects (Skinner et al., 2005). More recently, it was 
demonstrated that FP is an excellent mucosal delivery vector, compared to recombinant DNA 
or VV (Ranasinghe et al., 2011; Trivedi et al., 2014), and that mucosal immunization induces 
better protective efficacy against HIV-1, compared to systemic vaccination (Belyakov et al., 
2006; Ranasinghe et al., 2007).  
Although most pathogens enter the body through mucosal sites, most vaccines are 
administered by the parenteral route, and only a few mucosal vaccines have been approved 
for human use. Vaccination via intramuscular (i.m.) and subcutaneous routes also leads to 
stimulation of systemic immune responses, but poorly promotes immune protection at 
mucosal membranes (Riese et al., 2014). Conversely, i.n. mucosal immunization can trigger 
humoral and cell-mediated immunity both at mucosal sites and systemically (Brandtzaeg, 
2010; Holmgren & Czerkinsky, 2005). The presence of high levels of IgAs in nasal lymphoid 
tissue and in the lungs, which are the respiratory pathways through which OPVXs infect 
animals and humans, can be fundamental for inhibition of viral attachment to the mucosal 
epithelium, and provide protection from infection (Pierantoni et al., 2015). Finally, i.n. 
vaccination is more practical than the i.m. route (Lycke, 2012), and should facilitate mass 
vaccination campaigns. The development of live-attenuated or inactivated mucosal vaccines 
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should therefore meet the needs for better protection against pathogens that penetrate through 
mucosal membranes (Neutra & Kozlowski, 2006).  
Several studies have demonstrated that combined systemic and mucosal prime/ boost 
immunization can enhance both the humoral and cellular arms of immune responses 
(Ranasinghe et al., 2006; Srivastava et al., 2008), and different immune outcomes have resulted 
from combinations of poxvirus vectors using prime/ boost vaccination regimens (Ranasinghe et 
al., 2006; Wijesundara et al., 2014). Moreover, vaccinations in which DNA priming is 
followed by a recombinant viral vaccine boost can elicit greater immunity when compared to 
the use of single immunogens (Lu, 2009; Radaelli et al., 2003; Radaelli et al., 2007; Wang et 
al., 2008). Combined vaccines can also elicit improved antigen-specific antibody responses 
(Vaine et al., 2010). 
In the present study, genetic vaccines were administered using in-vivo electroporation 
(e.p.) followed by i.n. administration of FP recombinants. After determination of the optimal 
schedules for these e.p. and i.n. immunizations, the mice were primed with a mix of four 
different DNA plasmids that carried the VV L1R, A27L, A33R, and B5R genes (4DNAmix) 
(Pacchioni et al., 2013), and then boosted with FP recombinants that carried the same VV 
genes (4FPmix). All of the mice primed with 4DNAmix and boosted with 4FPmix were 
protected after a challenge with the highly pathogenic VVHID-J, which correlated with a 
neutralizing titer against the VV A27 envelope protein.  
 
2. Materials and methods 
2.1. Cells 
Primary fibroblasts were prepared from specific-pathogen-free chick embryos (Charles River 
Laboratories, Wilmington, MA, USA) and grown in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 5% heat-inactivated calf serum (Gibco Life Technologies, 
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Grand Island, NY, USA), 5% Tryptose Phosphate Broth (Difco Laboratories, Detroit, MI, 
USA), 100 U/ml penicillin and 100 mg/ml streptomycin. Green monkey kidney (Vero) cells 
(American Type Culture Collection, Rockville, MD, USA) were grown in DMEM 
supplemented with 10% heat-inactivated calf serum, 100 U/ml penicillin and 100 mg/ml 
streptomycin. Splenocytes from BALB/c mice were grown in RPMI with glutamine, 10% 
heat-inactivated foetal calf serum, and 100 U/ml penicillin and 100 mg/ml streptomycin 
(complete medium) and frozen in 90% foetal calf serum and 10% dimethylsulfoxide. 
 
2.2. Viruses 
The highly pathogenic IHD-J strain of VV (VVIHD-J) was supplied by S. Dales (University of 
Western Ontario, London, Canada) (Wilton et al., 1986), and it was used as the challenging 
virus (1 ×107 PFU/mouse, i.e., 5-fold the LD50), with i.n. administration. VVIHD-J was grown 
in Vero cells, then amplified, purified on discontinuous sucrose density gradient, and titrated, 
as described previously (Pacchioni et al., 2013). The 4FP recombinants, FPL1R, FPA27L, FPA33R, 
and FPB5R, that expressed the VV L1, A27, A33, and B5 proteins, respectively, were 
generated in our laboratory by in-vivo homologous recombination (Pozzi et al., 2009). They 
were then amplified in chick embryo fibroblasts and purified on discontinuous sucrose 
gradients, as described previously (Soprana et al., 2011). Gene insertion was performed 
downstream of the VV H6 early/ late promoter (Rosel et al., 1986), inside the 3-β-
hydroxysteroid dehydrogenase 5-delta 4 isomerase gene, which was interrupted by a multiple 
cloning site.  
 
2.3. Plasmids  
The expression plasmids pcDNA3.1A27L, pcDNA3L1R, pcDNA3A33R, and pcDNA3B5R were 
constructed by insertion of the same genes used for the generation of the 4FP recombinants, 
 9    
as described previously (Bissa et al., 2013). These were used to excise the genes to be inserted 
into the pVAX expression plasmid (Invitrogen Corp., San Diego, CA, USA) that contained 
the kanamicin resistance gene, and generated the pVAXA27L, pVAXL1R, pVAXA33R, and 
pVAXB5R, respectively, before their amplification. Here, pcDNA3L1R, pcDNA3A33R, and 
pcDNA3B5R were cut with HindIII/XhoI, whereas pcDNA3.1A27L was cut with HindIII/NotI, 
with all inserted into the same sites of the previously cut pVAX. Transformation was 
performed using DH5 competent bacteria. Bacterial selection was performed using the 
forward L1R V210 (5’ GGG GGG ATC CCA TTT AGT ATC CTA AAA TTG AAT TGT 
AAT TAT CGA TAA TAA ATG GGT GCC GCA GCA 3’) and reverse V211 (5’ GGG GCT 
CGA GAG AAA AAC GAG ATT TTC AGT TTT GCA T 3’) primers, the forward A33R 
V186 (5’ GGG AAG CTT TAT CAT GAT GAC ACC AGA AAA CGA CGA 3’), and 
reverse V212 (5’ GGG GTC GAC AAT ATT AGT TCA TTG TTT TAA CAC AAA 3’) 
primers; the forward B5R V206 (5’ GGG GGT CGA CCA TTT AGT ATC CTA AAA TTG 
AAT TGT AAT TAT CGA TAA TAA ATG AAA ACG ATT TCC 3’) and reverse V207 (5’ 
GGG GAA GCT TAG AAA AAG GAG ATA TTT ACG GTA GCA A 3’) primers, and the 
forward A27L V208 (5’ GGG GAG ATC TCA TTT AGT ATC CTA AAA TTG AAT TGT 
AAT TAT CGA TAA TAA ATG GAC GGA ACT CTT 3’) and reverse V209 (5’ GGG GGT 
CGA CAG AAA AAG GAG ATA TTT ACT CAT ATG G 3’) primers. Amplifications were 
performed as described previously (Zanotto et al., 2011), using 2.5 mM MgCl2 and 2 mM 
MgSO4, with annealing at 57 °C for 30 s (for A33R, B5R) or 61 °C for 30 s (for L1R, A27L), 
and extension at 72 °C for 45 s (for L1R, A33R, A27L) or 1 min (for B5R). The mixture of 
equal concentrations of the four recombinants was then prepared (4DNAmix). 
PcDNA3gagpol was used as an irrelevant negative control, and is called DNAgagpol (Zanotto 
et al., 2010). Both pcDNA3 and pVAX contain the human CMV promoter, but only pVAX 
has been approved for use in humans.  
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2.4. Immunization protocols 
Five groups of 8-week-old BALB/c female mice were used (Charles River Laboratories, 
Wilmington, MA, USA), as seven mice/group. Before each immunization, the mice were 
anaesthetized by i.m. injection of 30-l of a mixture of 3.5 l Rompun (stock, 20 mg/ml; 
Bayer SpA, Milan, Italy) plus 5.7 l Zoletil 100 (Virbac Srl, Milan, Italy) and 35.7 l 
phosphate-buffered saline without Ca2+ and Mg2+ (PBS–). The vaccination course consisted of 
priming with two e.p. administrations of the plasmid recombinants (i.m. injections followed 
by electroporation), and the boost with two i.n. administrations of the FP recombinants. 
Briefly, for the e.p., two 25-ms transcutaneous low-voltage electric pulses were administered 
(amplitude, 150 V; interval, 300 ms) at the injection site via a multiple-needle electrode 
connected to the e.p. apparatus (CliniporatorTM; IGEA Srl, Carpi, Italy). Each immunization 
was performed at two-week intervals. Two weeks after the last immunization, the mice were 
i.n. challenged with a lethal dose of VVIHD-J. 
Five different immunization protocols were followed (Fig. 1) using: (i) DNAgagpol 
plasmid (40 g/mouse), followed by FPgagpol recombinant (4 ×106 PFU/mouse; G1); (ii) 
DNAgagpol plasmid (40 g/mouse), followed by 4FPmix recombinants (1 ×106 PFU of each 
recombinant/mouse; G2); (iii) 4DNAmix (10 g of each recombinant/mouse), followed by 
FPgagpol recombinant (4 ×106 PFU/mouse; G3); (iv) 4DNAmix (10 µg of each 
recombinant/mouse), followed by 4FPmix recombinants (1 ×106 PFU of each 
recombinant/mouse; G4); (v) 4FPmix recombinants (1 ×106 PFU of each 
recombinant/mouse), with no DNA priming; G5). Bleeding was performed from the retro-
orbital eye plexus before the first immunization (Fig. 1, T0), before each of the first and 
second FP boosts (Fig. 1, T1, T2), and just before the challenge (Fig. 1, T3). The plasma 
fraction was aliquoted and frozen at -80 °C.  
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All of the mice were maintained according to the Italian National Guidelines and the 
EU Directive 2010/63/EU for animal experiments. They were observed for signs of disease, 
weighed daily, and provided with food and water ad libitum. Every effort was made to 
minimize their suffering, and based on the predetermined criterion of loss of >30% body 
weight, they were euthanized. Approval for this study was granted by the Ethical Committee 
of the University of Milan.  
 
2.5. ELISA 
The mouse plasma samples were tested for antibodies against the VV-specific L1, A27, A33, 
and B5 proteins. Mixtures of these L1, A27, A33, and B5 proteins (NIH Biodefense and 
Emerging Infections Research Resources Repository, NIAID), or alternatively, the individual 
proteins, were plated as 100 ng of each protein/well in 96-well microtiter plates (MaxiSorp; 
Nunc, Naperville, IL, USA) in 0.05 M carbonate-bicarbonate buffer, pH 9.6, and incubated 
overnight at 4 °C. ELISAs were performed in triplicate, essentially as described previously 
(Radaelli et al., 2010), using the pooled sera of each group of mice from T0, T1, T2, and T3 
(see Fig. 1). For the protein mixtures, the sera were diluted 1:500; for the single L1, A33, and 
B5 proteins, the sera dilutions were 1:100; for the A27 protein, the sera dilutions were 1:500.  
The reactions were revealed using a 1:2,000 dilution of goat anti-mouse horseradish-
peroxidase-conjugated serum (DakoCytomation, Glostrup, Denmark) and 
tetramethylbenzidine substrate (Sigma). The pre-immunization mouse sera (Fig. 1, T0) were 
used as negative controls. The absorbance of each well was read at 450 nm using a Microplate 
Reader 550 (Bio-Rad, Hercules, CA, USA).  
 
2.6. Splenocyte preparation 
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Two out of the seven mice per group were sacrificed by neck dislocation two weeks after the 
last vaccination and their spleen was removed; an exception was for G3, where only one 
mouse was used, as two in this group died before the challenge for nonexperimental reasons. 
Briefly, the spleen was laid on a 40-m nylon cell strainer (Corning Incorporated, NY, USA) 
and mechanically disrupted for 2 min with a flat plastic piston. The cells were passed through 
the filter using 6 ml RPMI complete medium. After centrifugation at 400× g for 10 min at 4 
°C, the supernatant was removed, and the pelleted cells were aliquoted at 2 ×106/vial for the 
interferon-γ (IFNγ) ELISPOT assay.  
 
2.7. ELISPOT assay 
Splenocytes from the immunized mice (1 ×106) were plated in triplicate into nitrocellulose 
96-well plates (HTS IP; Millipore, Bedford, MA, USA) that had been pre-coated with 5 µg/ml 
rat anti-mouse IFNγ antibody (clone R4–6A2; BD Biosciences Pharmingen, San Diego, CA, 
USA). The cells were stimulated for 48 h at 37 °C in RPMI complete medium containing 10 
µg/ml of each of the A27, A33, B5, and L1 proteins individually. Unstimulated cells were 
used as the negative control, and 2 g/ml concanavalin A (Sigma-Aldrich) as the positive 
control. The plates were developed according to the manufacturer instructions (BD™ 
ELISPOT; BD Biosciences). The specific spots were enumerated using a reader (Transtec 
1300 ELISPOT Reader; AMI Bioline, Buttigliera Alta, Turin, Italy), and analyzed using the 
ImmunoSpot image analysis software (A.EL.VIS GmbH, Hannover, Germany). IFN-
secreting spot-forming cells (SFCs) were counted, as the mean numbers per million assessed, 
including subtraction of the number of SFCs in the absence of stimulation. 
 
2.8. Determination of VVIHD-J LD50 for mice i.n. challenge 
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Preliminary tests were performed with female BALB/c mice to evaluate the VVIHD-J LD50 
after administration of different concentrations of the DNAgagpol and FPgagpol 
recombinants, carrying the irrelevant gagpol gene of HIV-1 (Table 1, LD50 tests 1-4). The 
immunization protocols were followed by challenges with different amounts of VVIHD-J, to 
evaluate the lowest dose that killed 50% of the mice (i.e., LD50). The VVIHD-J challenge virus 
was administered i.n. in 30 l PBS– through a plastic pipette tip after anesthetizing the mice, 
as described previously (Bissa et al., 2013). All of the mice were followed daily, with 
measurements of their weight, and monitoring for disease symptoms.  
 
2.9. Virus neutralization assays 
The neutralizing activities of the mice sera obtained before the challenge were determined by 
measuring the extent of in-vitro inhibition of VVIHD-J infectivity. The assays were performed 
by pre-incubation of an equal volume of VVIHD-J with heat-inactivated mouse serum, used at 
different dilutions in 48-well plates, for 1 h at 37 °C. The viral titer was adjusted to provide 
approximately 4 ×102 PFU VVIHD-J/ml in the assays. The infection was performed in 
duplicate on Vero cells, and was allowed to proceed for 1 h at 37 °C. The same amount of 
virus incubated with DMEM was used as the control. Three days later, 1.5% neutral red was 
added, and the plaques were counted the next day, as described previously (Pacchioni et al., 
2013). In the preliminary assays, sera from the T3 bleeding were pooled to perform the 
neutralization tests for each group. For the sera from G2 and G4, in which some or all of the 
mice were protected, these were also tested individually. Neutralization was expressed as the 
percentage of inhibition of infectivity compared to the control, where the virus was incubated 
with DMEM only. 
 
2.10. Statistical analysis 
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Statistical analysis was performed using one-way ANOVA parametric tests and Bonferroni 
analysis of variance, with the GraphPad Prism software, version 2.0. The statistical 
significance was set as p <0.05 (*), p <0.01 (**), and p <0.001 (***). 
 
3. Results  
3.1. Specific humoral and cellular immunity is elicited in mice primed with 4DNAmix and 
boosted with 4FPmix 
With the aim to develop a protective vaccination strategy against OPXV infections, five 
different immunization protocols were compared for their ability to induce antibodies against 
the VV L1, A27, A33, and B5 proteins expressed by DNA or FP recombinants administered 
alone or in combination. The specific humoral responses were measured by ELISA, using 
pooled sera from immunized mice and either a mix of all of these proteins (Fig. 2A) or the 
individual proteins (Fig. 2B) as the plate-bound antigens. As expected, the control mice of G1 
did not show any specific antibody response against any of the proteins tested (Fig. 2A). In 
contrast, the mice vaccinated with 4DNAmix plus 4FPmix (G4) showed significantly higher 
antibody titer against the pooled VV proteins, as compared to the other experimental groups 
at all of the bleeding times (p <0.001). Interestingly, a significant increase in antibody titers 
was observed after the FP boost (i.e., T2 and T3 vs. T1; p <0.001). The single antigens were 
then plated to test the specificity of the antibodies for each protein that were induced by these 
vaccinations (Fig. 2B). None of the groups showed humoral responses against L1. In contrast, 
both G3 and G4 showed humoral responses against A27, which was significantly greater for 
G4 (G4 vs. G3; p <0.001), where a further significant increase was also observed after the FP 
boosts (i.e., T2 and T3 vs. T1; p <0.001). For A33, with G2 and G4, humoral responses were 
measurable only at T3, which were significantly greater for G2 than the other groups (p 
<0.001), although it never reached the level attained with A27. Against B5, there was a 
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significantly greater response only at T3 after the second FP boost for G2, G4, and G5 (p 
<0.001). 
To determine the vaccine-induced cell-mediated immunity, the secretion of IFNγ by 
splenocytes from mice that were immunized following the different immunization regimens 
was assessed using the IFNγ-ELISPOT assay. Following the stimulation with A27, the 
immunized mice from G2, G3, G4, and G5 showed significantly greater numbers of SFCs 
(Fig. 3), as compared to those observed using splenocytes from the control mice (G1). 
Interestingly, the number of SFCs was significantly greater in the mice immunized with 
4DNAmix + 4FPmix (G4 vs. G2; p <0.05). Conversely, stimulation with A33, B5, and L1 did 
not result in any significant increase in the numbers of SFCs in any of these experimental 
groups (data not shown). 
 
3.2. The VVIHD-J challenge shows higher LD50 when the FP vaccination is performed i.n. 
As previous data from our laboratory were obtained from BALB/c mice immunized i.m. and 
subcutaneously, preliminary challenge tests were performed to determine the VVIHD-J LD50 
when administered i.n.. To determine whether the DNA e.p. and the FP i.n. administration 
routes affect the LD50 of VVIHD-J, two groups of BALB/c mice were vaccinated twice with the 
irrelevant DNAgagpol or FPgagpol (e.p., i.n., respectively) and challenged with increasing 
VVIHD-J doses. Here, the LD50 remained unvaried at 2 ×10
5 VVIHD-J PFU/mouse when using 
either the previously determined i.m. immunization with 100 µg of each recombinant DNA 
(Bissa et al., 2013) or the e.p. immunization with 40 µg of the DNAgagpol recombinant 
(Table 1, LD50 test 2). Conversely, in mice immunized i.n. with FPgagpol (1 ×10
7 PFU), the 
LD50 increased to 5 ×10
6 PFU/mouse (Table 1, LD50 test 3), 25-fold greater compared to the 
LD50 observed by immunization with the same FP recombinants given i.m. (Bissa et al., 2013). 
To reduce the amount of the VVIHD-J challenge, other tests were performed by reducing the 
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titer of the FPgagpol immunogen from 1 ×107 PFU to 4 ×106 PFU (Table 1, LD50 test 4). 
Using this FPgagpol dose, the LD50
 was reduced from 5 ×106 PFU/mouse to 2 ×106 
PFU/mouse. The challenge for the different immunization protocols was then performed 
using 5-fold the LD50 determined for FP (i.e., 1 ×10
7 VVIHD-J PFU/mouse). 
 
3.3. Priming with 4DNAmix and boosting with 4FPmix protects all of the mice from the 
challenge 
To determine the protective efficacy of the vaccine-induced immune responses, the mice of 
G1 to G5 that were not sacrificed for spleen removal were taken beyond T3 to the challenge 
with VVIHD-J, after which they were monitored for weight loss and survival. Soon after the 
experimental challenge, all of the mice progressively lost 25% to 30% of their weight, up to 
days 4-5 post challenge (p.c.) (Fig. 4A). This weight loss progressed with no relevant 
differences among G1, G3, and G5, and all of the mice of these three groups died between 
day 4 p.c. and day 14 p.c. Conversely, 100% of the mice in G4, and 20% of those in G2, 
regained weight after day 3 p.c. and day 5 p.c., respectively, and thus survived the i.n. 
challenge with a 5-fold improvement in the LD50 (Fig. 4B). These data demonstrate that DNA 
priming and FP boosting is the most effective way to induce effective protection for these 
mice against VVIHD-J. 
 
3.4. Pre-challenge neutralizing activity against VVIHD-J correlates with post-challenge 
mouse survival 
To determine the putative pre-challenge immune correlates of this protection against VVIHD-J, 
viral neutralization assays were performed using the sera from T0 and T3 (Fig. 5). This 
included both pooled sera from the mice of each experimental group and the sera from each 
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mouse of the G2 and G4 protocols, where protection was obtained for 20% and 100% of the 
mice, respectively.  
For the pooled sera, inhibition of viral infectivity was generally higher in the pre-
immune serum (T0) than after the third immunization (T3), except for G4, where the mice 
were all seen to be protected. The sera from these G4 mice showed low, although significant, 
inhibition of infectivity at T3 at 1:40 dilution (T3 vs. T0; p <0.05) (Fig. 5A). As one of the five 
challenged mice from G2 was also protected, the sera from both G2 and G4 were separately 
analyzed at T0 and T3 for each of the five challenged mice of these groups, to define any 
correlation between the pre-challenge viral neutralizing activity and the p.c. mice survival 
(Fig. 5B). The pre-immune sera of all of the mice of G2 showed higher neutralizing activity at 
T0 than T3, except for mouse no. 1, which was the only one that survived the challenge, and 
showed significantly higher viral inhibition at 1:50 dilution (T3 vs. T0, p <0.001). Conversely, 
most of the challenged mice of G4 showed higher inhibition of infectivity at T3 than T0 with 
the exception of mouse no. 5 (Fig. 5B).  
 
4. Discussion 
The lack of preventive vaccines against some infectious diseases and the emergence of new 
pathogens underlines the need for new and more effective immunogens. In particular, safer 
vaccines against OPXV infection of animals and humans are still an important issue, as a 
result of the reduction in the ‘herd immunity’ following discontinuation of the smallpox 
vaccination campaign. At present, the development of safer vaccines against OPXV 
(Artenstein, 2008; Poland, 2005; Wiser et al., 2007) has also been encouraged by increased 
human MPXV zoonotic infections (Hutin et al., 2012) or by problems that might arise if there 
is a deliberate release of variola virus for terrorist purposes.  
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It has already been shown that different viral vectors and their combinations can 
significantly influence vaccine efficacy (Ranasinghe et al., 2011) and enhance immune 
responses, depending on inoculation site and recruitment of antigen-presenting cells 
(Hervouet et al., 2014; Trivedi et al., 2014). Local administration of vaccines to mucosal 
tissues can indeed elicit IgAs and cytotoxic T lymphocytes, which can have pivotal roles in 
neutralizing viruses at their natural port of entry (Brandtzaeg, 2007), and in elimination of 
infected cells.  
In the present study, the four DNA and four FP recombinants all contained the VV 
L1R, A27L, A33R, and B5R genes and were administered following e.p. (for DNA) and i.n. 
(for FP recombinants) routes and heterologous prime/ boost immunization regimens. Our aim 
was to compare different vaccination protocols and to evaluate the humoral and cell-mediated 
responses, as well as protection for mice challenged with the highly pathogenic VVIHD-J. Here, 
we have demonstrated that: (i) the specific humoral response correlates with protection; (ii) 
only protected mice show specific VVIHD-J neutralizing antibodies; (iii) after i.n. FP 
vaccination, mice are protected against higher VVIHD-J challenges; (iv) the putative protective 
role of the cellular immune response appears to be ascribed to only the A27 protein; and (v) 
all of the mice were protected when primed with 4DNAmix and boosted with 4FPmix. 
Although still controversial, the critical role of the antigen-specific humoral response 
against OPXV has already been described (Edghill-Smith et al., 2005; Panchanathan et al., 
2006), and passive transfer of VV-specific sera was shown to confer protection in both mice 
and monkeys (Golden et al., 2011). In the present study, although the magnitude of the 
humoral response was highly variable, a correlation with mice survival was shown soon after 
the first immunization. In particular, the A27 antigen was the most immunogenic, as also 
demonstrated previously for the MPXV A29 ortholog of VV A27 (Heraud et al., 2006), 
whereas no response was elicited by L1 for all of the protocols used here.  
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The protective efficacy of genetic immunization was demonstrated previously both in 
mice and nonhuman primates (Hooper et al., 2003; Hooper et al., 2007). However, in the 
present study, 4DNAmix of G3 and 4FPmix of G5 elicited antibodies against A33 and B5, 
although they did not protect the mice. Surprisingly, irrelevant DNA in G2 increased the 
4FPmix antibody response against A33, which was not shown in G5, when only 4FPmix was 
used.  
Neutralization of infectivity generally correlates with the level of antibodies against 
the viral surface antigens, and is usually a direct indication of vaccine efficacy and protection. 
In the present study, natural in-vitro virus-neutralizing antibodies were present before 
immunization, and these might be a characteristic of this animal species. However, although 
we cannot provide a reason for this neutralizing activity by pre-immune sera, only the 
protected mice showed increased neutralization titers before the challenge. 
When 10 µg DNA of each antigen was administered e.p., this appeared to be as 
efficient as 100 g DNA administered i.m. (Bissa et al., 2013), as the VVIHD-J challenge dose 
remained unvaried. In contrast, an increase in the dose of the VVIHD-J challenge was necessary 
after i.n. immunization with FP recombinants, which also provided an advantageous reduction 
in the amount of immunogen. Indeed, although the 2 ×106 PFU VVIHD-J challenge was 
previously found to be lethal after i.m. immunization with all of the FP recombinants, i.n. 
administration of the same immunogens raised the LD50 here by 25-fold, which indicates that 
the efficacy of FP vaccines can increase remarkably when administered by this route. This 
might be due to the same i.n. administration used for both the vaccine and the challenge virus, 
which would indicate that this i.n. vaccine can induce prominent mucosal immunity that is 
effective against the incoming VVIHD-J. It has already been shown that, compared to modified 
vaccinia Ankara and VV, FP recombinants can better promote recruitment of dendritic cells and 
induce CD8+ T-cell–mediated immunity. Their i.n. delivery can recruit unique antigen-
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presenting cells to the lung mucosa, when compared to other recombinant poxvirus vectors 
(Trivedi et al., 2014), by eventually conferring a different T-cell functionality (Furuhashi et al., 
2012). Similarly, canarypox recombinants can elicit qualitatively distinct cytokine and 
chemokine profiles compared to attenuated VV vectors in rhesus macaques (Teigler et al., 2014). 
Moreover, viral interference and competition for penetration cannot be excluded, as FP-based 
recombinants might bind to the same poxvirus receptors and hamper VVIHD-J penetration 
through the airway mucosa (Laliberte & Moss, 2014).  
The protective role of the cytotoxic T-lymphocyte response after OPXV vaccination is 
still debated (Buchman et al., 2010), although vaccines that target T-cell epitopes also appear 
to be protective (Goulding et al., 2013; Moise et al., 2011; Snyder et al., 2004). Moreover, 
vaccination with VV was also effective when there was dysfunction in the humoral response, 
although not in patients with T-cell–related immunodeficiencies (Golden & Hooper, 2013). 
Our data also confirm the efficacy of both DNA and FP recombinants for stimulation of 
CD8/IFN cell-mediated immunity, with high specific response induced by the A27 antigen. 
In particular, cellular immunity induced by recombinant genetic and viral vaccines 
administered alone was lower than that observed when these vaccines were administered in 
combination, and the cellular immune responses against A27 shown here for G2, G3, and G5 
were not significantly different from that of G1. In contrast, significantly greater numbers of 
IFN-producing SFCs were measured for the G4 mice, which were all protected. This survival 
was also found to be inversely correlated with the weight decrease, which was initially similar 
in all of the groups after the VVIHD-J challenge, but all of the G4 mice recovered their weight, 
as also for the only protected mouse of G2. 
Overall, this protection appears to have been mainly determined by the humoral 
response, which was endowed with a specific virus-neutralizing activity. This was the case for 
all of the mice immunized with 4DNAmix followed by 4FPmix, thus showing the efficiency 
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of this prime/ boost vaccination regimen, and the fundamental contribution of 4FPmix. As our 
antibody determination was performed on peripheral blood, it could not have discriminated 
among the different IgG, IgM, and IgA isotypes to estimate the contribution of the mucosal 
IgAs. This isotype is mainly present at the i.n. inoculation site, and it might have been the 
main effector of this protection, considering that both the 4FPmix boost and the VVIHD-J 
challenge were performed using the same administration route. 
This combined use of the L1 and A27 envelope proteins of the intracellular mature 
virions and the A33 and B5 proteins of the extracellular virions has already been shown to 
protect mice better than the same proteins administered alone (Hooper et al., 2003). However, 
in the present study, the humoral, neutralizing, and cellular responses were mainly raised against 
the A27 surface protein, and thus it would be interesting to determine whether protection can 
also be obtained by administration of only DNAA27 followed by FPA27, using this prime/ boost 
immunization protocol.  
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Figure legends 
Figure 1. Immunization protocols.  
Five different regimens (G1-G5) were followed using 7 mice per group. The four genetic 
recombinants expressing the VV L1R, A27L, A33R, and B5R genes (4DNAmix) were used for 
priming, and the viral recombinants expressing the same four genes (4FPmix) were used for 
the boost. DNAgagpol and FPgagpol recombinants containing HIV-1 gagpol genes were used 
were used as irrelevant immunogens. Each plasmid was administered in vivo by e.p. (10 
µg/recombinant/mouse), and each virus was administered i.n. (1 ×106 
PFU/recombinant/mouse). The VVIHD-J challenge virus was administered i.n. at 1 ×10
7 PFU/ 
mouse (i.e. 5-fold the LD50 determined for FPgagpol). Mice were bled before the first 
immunization (T0), before the first and second FP boosts (T1, T2) and just before the VVIHD-J 
challenge (T3).  
 
Figure 2. Analysis of specific humoral responses by ELISA.  
The sera of the mice of the different groups were examined at different times post 
immunization as the pooled sera diluted 1:500 for the protein mixture (A) and the sera diluted 
1:100 for the individual L1, A33, and B5 proteins and 1:500 for the individual A27 protein 
(B). (A) Anti-L1, -A27, -A33 and -B5 antibody levels were determined using a mixture of all 
of the proteins (L1+A27+A33+B5) as plate-bound antigens. Data are means of the animal 
sera for each group. G4 mice showed significant increases in specific antibody titers from T1. 
(B) The individual proteins were used as plate-bound antigens. None of the groups showed 
humoral responses against L1. For A27, the humoral response was significantly greater for 
G4 (G4 vs. G3; p <0.001) and significantly increased over time (G4: T2 and T3 vs. T1; p 
<0.001). For A33, the humoral response was significantly greater for G2 than the other groups 
(p <0.001). For B5, the humoral response was significantly greater only at T3 for G2, G4, and 
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G5 (G2, G4, G5 vs. G3; p <0.001). Statistical differences are shown (one-way ANOVA 
parametric tests, Bonferroni analysis of variance): ***, p <0.001. 
 
Figure 3. Analysis of the functional virus-specific T-cell responses to A27 antigen using 
IFNELISPOT assays.  
IFNγ secretion by splenocytes was measured in mice immunized following the different 
immunization regimens shown in Fig. 1. Stimulation with A33, B5, and L1 did not result in 
any significant increase in spot-forming cells SFCs (data not shown). Only when stimulation 
was performed with A27, there were significant increases in IFN SFCs in G2 to G5, 
compared to G1 as negative control. Comparison among the different groups also showed 
significant increase of G4 vs. G2 (p <0.001). Statistical differences are shown (one-way 
ANOVA parametric tests, Bonferroni analysis of variance): ***, p <0.001. Data are means of 
the SFC/106 splenocytes for mice of each group. 
 
Figure 4. Effects on weight loss and protective efficacy against VVIHD-J challenge 
induced by the different immunization regimens.  
All of the mice challenged with VVIHD-J were monitored daily for the post-chalenge (p.c.) 
percentage weight loss (A) and survival (B). (A) Data are means of percentage weight loss of 
each group. Mice progressively lost weight until day 4 p.c., as 25% to 30%. There were no 
relevant differences among most of the groups, but G4 mice and one mouse of G2 started to 
regain weight after days 3 and 5 p.c., respectively. (B) All of the G4 mice and one mouse of 
G2 were protected and survived, whereas the remaining mice of G2, G3, and G5 died from 
days 5 to 14 p.c.. All of the control G1 mice died on days 4 or 5 p.c.. 
 
Figure 5. Inhibition of viral infectivity by the different immunization protocols.  
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Viral neutralization assays were performed on Vero cells using sera before the first 
immunization (T0) and just before the challenge (T3). Plaque reduction was quantified, and 
expressed as percentages of inhibition of infectivity. (A) When using pooled sera from all of 
the groups of mice, only those from G4 showed significant inhibition of infectivity (G4 vs. 
G2, G3, G5; p <0.05). (B) Only the sera from G2 (no. 1 survived) and G4 (all protected) mice 
were separately analyzed for correlation between neutralizing activity and survival. For the 
G2 mice, only animal no. 1 showed significantly higher viral inhibition (T3 vs. T0; p <0.001). 
Most of the G4 mice showed inhibition of infectivity, which was significantly greater for one 
mouse (no. 3: T3 vs. T0, p <0.01). Statistical differences are shown (one-way ANOVA 
parametric tests, Bonferroni analysis of variance): *, p <0.05; **, p <0.01; ***, p <0.001.  
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Table 1. Determination of LD50 by inoculation of different doses of VVIHD-J in immunized mice. 
 
 
LD50 
test 
Immunogen 
Route of 
administration 
Concentration 
VVIHD-J i.n. 
challenge 
(PFU/mouse) 
Survival 
% 
 1 
prime  4DNAmixa   
boost   4FPmixa 
e.p. 
i.n. 
40 g 
4x107 PFU/mouse 
1 ×106 100 
2 DNAgagpol  e.p. 40g 2 ×105 50 
3 FPgagpol   i.n. 1x107 PFU/mouse 5 ×106 50 
4 FPgagpol   i.n. 4x106 PFU/mouse 2 ×106 50 
 
a, mix comprising equal amounts of each of the four components (VV L1R, A27L, A33R, B5R) 
 
